US FDA Advisors' Push For BA.4/BA.5 COVID-19 Boosters Sets Up Regulatory, Manufacturing Crunch

If FDA wants to follow its external experts' advice on new booster composition, it would likely have to authorize BA.4/BA.5-targeting boosters on preclinical and manufacturing data only, and companies would have to quickly pivot manufacturing.

ice hockey player
FDA was urged to go where the puck is going when picking strains for updated COVID-19 vaccines. • Source: Shutterstock

US Food and Drug Administration advisors voted overwhelmingly in favor of recommending inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines, with most of those in favor of the vaccine update recommending a bivalent product that includes both the prototype vaccine strain and the Omicron sub-lineage BA.4/BA.5 strain.

The Vaccines and Related Biological Products Advisory Committee's 19-2 vote in favor of Omicron boosters on 28 June, combined with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers